Heparin protocols: what happens when the therapeutic range changes?Lenz, J
In patients on dialysis, greater residual kidney function (RKF) is associated with improved survival; however, whether this benefit is apparent over a wide range of RKF values or is limited to a reduction in death from cardiovascular causes is uncertain. In a longitudinal study of over 39,000...
o APTT is used to monitor heparin, heparin is a indirect thrombin inhibitor, this is why we want pts aPTT to be 1 – 2 times the normal value range Heparin therapeutic goal is 1 – 2 times the normal value range. Anticoagulants do not dissolve clots ...
8. Pegaptanib from biological target definition to current therapeutic use 9. Selective versus non-selective anti-VEGF drugs side effects: an ongoing debate from the bench to the eye of patients 10. Risk of inhibiting VEGF beyond the eye 11. Tachyphylaxis: a relevant issue in anti-VEGF therap...
They are carried out essentially at the end of ECC, rather after the neutralisation of heparin, to guide the therapeutic strategy. The recommendation is that they should be included in algorithms. 7. Liver transplantation Liver transplantation (LT) is currently the only curative treatment for ...
Basophils contain the anticoagulant heparin, crucial in preventing blood clot formation. It binds to a protein called antithrombin III (AT). This link induces a conformational change in AT, which activates it significantly. [4] Activated AT is a potent inhibitor of thrombin—factor IIa—and fa...
aggregatory effect of sodium nitroprusside, in humans, sildenafil has no effect on bleeding time when taken alone or with aspirin.65 In an animal study, the combination of heparin and sildenafil had an addi- tive effect on bleeding time; however, this interaction has not been studied in ...
The human immunodeficiency virus type 1 (HIV-1) trans-activator of transcription protein Tat is an important factor in viral pathogenesis. In addition to its function as the key trans-activator of viral transcription, Tat is also secreted by the infected
The risk profiles of drugs can vary considerably, and a drug is typically considered “high-risk” when it has a narrow therapeutic range of reported history of verified severe ADEs [60]. The risk can also be heightened due to specific formulations, e.g., depot-preparations, intrathecal ...
asthma (Spycher et al.2010; Lødrup Carlsen and Carlsen2012). However, the characteristics used for the definition of the various phenotypes are not necessarily directly related to the underlying pathogenetic process(es). Aiming at the development of personalized therapies, i.e., therapeutic ...